Fig. 3.

Voreloxin or cytarabine at MTD causes a reversible decrease in myeloid and lymphoid cells in bone marrow and peripheral blood CD-1 mice received vehicle, voreloxin, or cytarabine on day 0 and 4. a Percent cellularity remaining in the bone marrow on days 6 (D6) and 12 (D12): Vehicle, 0.17% methanesulfonic acid in 5% sorbitol IV q4d ×2 and water SC tid q4d ×2; Cytarabine, 60 mg/kg SC tid q4d ×2; Voreloxin, 20 mg/kg IV q4d ×2. b Peripheral blood was isolated on days 6, 8, and 12 for analysis. Neutrophils, lymphocytes, and platelets in circulation (×10³/μl) following treatment: (Filled square), vehicle; (Filled triangle), cytarabine, 60 mg/kg SC tid q4d ×2; (Filled circle), voreloxin, 20 mg/kg IV q4d ×2. Black arrow represents the three cytarbine doses, and the gray arrow represents the voreloxin dose